Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06544330 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
A Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, sponsored by Synthekine.
- Active
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 5
- Study locations
NCT06544330 is a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis that is active but no longer recruiting, run by Synthekine. The registered enrollment target is 48 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06544330, a Phase 1 study of Systemic Lupus Erythematosus and Lupus Nephritis, is active but no longer recruiting, sponsored by Synthekine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
Conditions Studied
Interventions
- DRUG SYNCAR-001
- DRUG STK-009
Study Locations (5)
Ohio
- The Cleveland Clinic Foundation - Cleveland
- Ohio State University Wexner Medical Center - Columbus
Arizona
- HonorHealth Research Institute - Scottsdale
New Jersey
- Hackensack University Medical Center - Hackensack
New York
- Feinstein Institutes for Medical Research - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2041-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06544330
The ClinicalTrials.gov registry entry for NCT06544330 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (87% lower). The listed sponsor is Synthekine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which SYNCAR-001 is the first listed.
NCT06544330 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Arizona, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06544330 about?
NCT06544330 is a clinical study titled "A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease". This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
What is the current status of trial NCT06544330?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-04-29. Estimated completion is 2041-04.
What conditions does trial NCT06544330 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis.
What interventions are being tested in trial NCT06544330?
The interventions under investigation include: SYNCAR-001 (DRUG), STK-009 (DRUG).
Who is sponsoring clinical trial NCT06544330?
This trial is sponsored by Synthekine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06544330 being conducted?
This trial has 5 study locations across Arizona, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.